Skip to main content


You are here

Remedy Pharmaceuticals - Drug Trial Results Could Change Stroke Treatment Forever, Saving And Improving Millions of Lives

Tuesday, May 5, 2015

Remedy Pharmaceuticals, Inc. today announced that the GAMES-RP study of the drug CIRARA™ (RP-1127) in severe stroke has successfully ended enrollment with 83 patients. Results from the study are expected in September 2015. 

Eighteen leading medical centers were involved in the GAMES-RP trial (in alphabetical order): Abington Memorial Hospital, Abington, PA; Cleveland Clinic, Cleveland, OH; Maine Medical Center, Portland, ME; Massachusetts General Hospital, Boston, MA; Medical University of South Carolina, Charleston, SC; Northwestern Memorial Hospital, Chicago, IL; Oregon Health & Science University Hospital, Portland, OR; Ohio State University/Wexner Medical Center, Columbus, OH; Rutgers (Robert Wood Johnson University Hospital), New Brunswick, NJ; Stanford University Medical Center, Stanford, CA; UMASS Memorial Medical Center, Worcester, MA; University of Arizona Medical Center - University Campus, Tucson, AZ; University of Florida, Jacksonville, FL; University of Louisville Hospital, Louisville, KY; University of Maryland Medical Center, Baltimore, MD; University of Utah Healthcare, Salt Lake City, UT; UPMC Presbyterian Hospital, Pittsburgh, PA; and Yale-New Haven Hospital, New Haven, CT.

Stroke is the second leading cause of death globally, with approximately 16 million victims each year, or one every other second of every day. About a third of all strokes result in death. Another third of victims will be permanently disabled, some even left in a vegetative state. The lifetime risk of stroke in men is 1 in 6; it’s 1 in 5 for women. 

Click here to read the entire press release.